Table 4.

Clinical Trials Utilizing Combination of DNA Damaging Agents with PARPi

Treatment	Clinical Trials Identifier	Phase	Status	Patient Population	Eligibility and Exclusion	Primary Endpoints	Secondary Endpoints
ABT-888 With Modified FOLFOX6	NCT01489865	I/II	Active, Not Recruiting	Metastatic PDAC with BRCA1/2, PALB2, FANC genes or strong family history suggestive of breast/ovarian cancer syndrome	No limitation on previous lines of therapy	Dose Limiting Toxicities	Objective response rate
FOLFIRI or Modified FOLFIRI and Veliparib	NCT02890355	II	Active, Not Recruiting	Unselected cohort of patients with Metastatic PDAC	Only one previous line of therapy prior	OS	Toxicity PFS Overall Response Rate Disease control rate Duration of response

Abbreviations: PDAC, Pancreas Ductal Adenocarcinoma; PFS, Progression Free Survival; OS, Overall Survival.